N.N. Blokhin Russian Cancer Research Center / Российский онкологический научный центр им. Н. Н. Блохина

Research facility

Location: Moscow / Moskau, Russian Federation (RU)

ISNI: -

ROR: https://ror.org/00ab9fg88

Show on Map:

Publications

(15)

Evaluation of Nectin-4 and Trop-2: Implications for Patient Outcomes and Therapy in Penile Cancer (2025) Mink JN, Eckstein M, Khalmurzaev O, Pryalukhin A, Geppert CI, Lohse S, Bende K, et al. Journal article Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice: an international survey. (2025) Hauschild A, Garbe C, Ascierto PA, Demidov L, Dreno B, Dummer R, Eggermont A, et al. Journal article The impact of the tumor microenvironment on the survival of penile cancer patients. (2024) Lohse S, Mink JN, Eckhart L, Hans MC, Jusufi L, Zwick A, Mohr T, et al. Journal article Evaluation of Prognostic Parameters to Identify Aggressive Penile Carcinomas (2023) Mink JN, Khalmurzaev O, Pryalukhin A, Geppert CI, Lohse S, Bende K, Lobo J, et al. Journal article Bedeutung von HPV-Status und p16 für die Prognose des Peniskarzinoms (2023) Mink JN, Khalmurzaev O, Pryalukhin A, Hölters S, Geppert CI, Lohse S, Bende K, et al. Journal article The prominent role of the S100A8/S100A9-CD147 axis in the progression of penile cancer (2022) Mohr T, Zwick A, Hans MC, Bley IA, Braun FL, Khalmurzaev O, Matveev VB, et al. Journal article IDKK1 inhibits canonical Wnt signaling in human papillomavirus-positive penile cancer cells (2022) Bley IA, Zwick A, Hans MC, Thieser K, Wagner V, Ludwig N, Khalmurzaev O, et al. Journal article, Review article miRNA expression characterizes histological subtypes and metastasis in penile squamous cell carcinoma (2021) Hiresh A, Heinzelmann J, Hoelters S, Khalmurzaev O, Pryalukhin A, Loertzer P, Heinzelbecker J, et al. Conference contribution Mirna expression characterizes histological subtypes and metastasis in penile squamous cell carcinoma (2021) Ayoubian H, Heinzelmann J, Hölters S, Khalmurzaev O, Pryalukhin A, Loertzer P, Heinzelbecker J, et al. Journal article Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. (2021) Bottomley A, Coens C, Mierzynska J, Blank CU, Mandalà M, Long GV, Atkinson VG, et al. Journal article

‹ 1 2 ›